

ALLEGATO B

Decreto Rettore Università di Roma “La Sapienza” n 2267/2021 del 09/08/2021

ILARIA BARCHETTA Curriculum Vitae ai fini della pubblicazione

Part I – General Information

Full Name	Ilaria Barchetta
Spoken Languages	Italian, English

Part II – Education

Type	Year	Institution	Notes
University graduation	2007	Sapienza University Rome, Italy	Degree in Medicine and Surgery <i>cum laude</i> Title of Thesis: <i>"Relationship between insulin resistance, metabolic syndrome and impaired glucose tolerance. The GENFIEV study"</i>
Post-graduate studies			
PhD	2011	Sapienza University Rome, Italy	PhD in Clinical and Experimental Hepatology Title of the Project: <i>"Relationship between hypovitaminosis D, metabolic syndrome, type 2 diabetes and NAFLD"</i>
Specialty	2016	Sapienza University Rome, Italy	Degree in Internal Medicine <i>cum laude</i> Title of Thesis: <i>"Adipose tissue inflammation, type 2 diabetes and ectopic fat: role of the adipose tissue dysfunction in intra-parenchymal fat accumulation and systemic inflammation in relation to glucose tolerance"</i>
Licensure	2008	Ordine dei Medici di Roma	Registration n. 56257
Advanced Professional Training Course (CAF)	2019	Sapienza University Rome, Italy	Degree in <i>"Pedagogy and Medical Teaching"</i>
Training course	2019	Lipari School on Computational Life Sciences – J.T. Schwartz International School for Scientific Research	Degree in <i>"Computational Metabolomics and Metabolic Diseases"</i>
Training course	2017	Oracle (C.R.O.)	Good Clinical Practice (GCP)
Advanced Professional Training Course (CAF)	2013	Sapienza University Rome, Italy	Degree in <i>"Statistical Methods for Biomedical Practice and Research"</i>
Advanced Professional Training Course	2011	Italian Society of Ultrasonography in Medicine and Biology (SIUMB)	Degree in <i>"Ultrasonography in Internal Medicine"</i>

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
2017	2020	Department of Experimental Medicine Sapienza University, Rome, Italy	<i>Post-doc fellow (Assegnista di Ricerca categoria B tipologia II)</i>
2016	2017	Department of Internal Medicine and Medical Specialties Sapienza University, Rome, Italy	<i>Post-doc fellow (Assegnista di Ricerca categoria B tipologia II)</i>
2015	2016	Diabetes and Endocrinology Unit Department of Clinical Sciences Lund University, Malmö, Sweden	<i>Post-doctoral researcher</i>
National Scientific Qualification for Academic positions			
2018	2024	Italian National Agency for the Evaluation of Universities and Research Institutes (ANVUR)	<i>National Scientific Qualification for Associate Professor for the SC 06/D2, SSD MED/13, Endocrinology</i>
2021	2030	Italian National Agency for the Evaluation of Universities and Research Institutes (ANVUR)	<i>National Scientific Qualification for Associate Professor for the SC 06/B1, SSD MED/09, Internal Medicine</i>
2021	2030	Italian National Agency for the Evaluation of Universities and Research Institutes (ANVUR)	<i>National Scientific Qualification for Associate Professor for the SC 06/N1 SSD MED/50, Applied Medical Technical Sciences</i>

IIIB – Clinical Appointments

Start	End	Institution	Position
12.2020	12.2021	Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy	<i>Dirigente Medico - UOC Medicina Interna DAI Medicina Interna, Scienze Endocrino-Metaboliche e Malattie Infettive</i>
2016	2020	Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy	<i>Post-doc fellowship with authorization to clinical activity in wards, day-hospital and outpatient clinics, Section of Endocrinology and Diabetes, Sapienza University of Rome. Supervisor: Prof. Maria Gisella Cavallo</i> <i>Co-investigator and Study Coordinator of clinical trials in type 1 and type 2 diabetes patients (see also Part VII)</i>
2007	2011	Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy	<i>Ph.D. with authorization to clinical activity at the Diabetes outpatient clinics, UOS Centro Aterosclerosi, Sapienza University. Supervisor: Prof. Maria Gisella Cavallo</i>

IIIC – Other Appointments

Editorial Activity

2021 - present	<i>Metabolism & Target Organ Damage</i>	<i>Member of the Editorial Board</i>
----------------	---	--------------------------------------

2020 - present	<i>Nutrition Metabolism and Cardiovascular Diseases</i>	<i>Member of the Editorial Board</i>
2020 - present	<i>Frontiers in Clinical Diabetes and Healthcare</i>	<i>Associate Editor for the section "Diabetes Geographic Inequalities"</i>
2020 - 2021	<i>Biomolecules</i>	<i>Topic Editor section "Clinical Diabetes"</i>
2020 - present	Italian Diabetes Society (SID)	<i>Member of the Editorial Committee</i>
2018 - present	WikiSID, the online platform on Diabetes of SID	<i>Member of the Steering Committee</i>
2014 - present	<i>Journal of Endocrinological Investigations</i>	<i>Member of the Editorial Board</i>

Part IV – Teaching experience

Year	Institution	Lecture/Course
2021	Sapienza University Rome, Italy	<i>Docente Master in Nutrizione Clinica e Metabolismo</i> Argomento: "NAFLD-NASH: inquadramento clinico e diagnostico"
Since 2021	Sapienza University Rome, Italy	<i>Docente cultore della materia</i> <i>Facoltà di Medicina e Odontoiatria</i> <i>Corso di Laurea in Medicina e Chirurgia, C.C.L. A</i> <i>Insegnamento di Metodologia Medico-Scientifica II</i>
2017 - 2020	Sapienza University Rome, Italy	<i>Assistente alla didattica e membro della commissione di esami</i> <i>Facoltà di Medicina e Odontoiatria</i> <i>Corso di Laurea in Medicina e Chirurgia, C.C.L. C</i> <i>Medicina Interna III</i>
2013 - 2021	Sapienza University Rome, Italy	<i>Correlatore di Tesi di Laurea Magistrale per studenti del Corso di Laurea Magistrale in Medicina e Chirurgia:</i> <ul style="list-style-type: none"> - "Associazione tra ipovitaminosi D e sindrome metabolica in un gruppo di soggetti obesi" candidata Marzia De Bernardinis - "Associazione dello SNP Cdx2 del gene del recettore della vitamina D con il Diabete di tipo 2" candidata Laura Bertocchini - "Valutazione dello stato di infiammazione subclinica in pazienti con DT2 e NAFLD/NASH ed effetti della supplementazione orale con vitamina D sui parametri infiammatori e di insulino-resistenza" candidata Flavia Agata Cimini - "La terapia con inibitori di pompa protonica nei pazienti affetti da diabete mellito di tipo 2 è associata a miglior controllo glicemico" candidato Damiano Calella - "I livelli di TSH sono associati con il bilancio della vitamina D e con la stagionalità in una popolazione di soggetti adulti eutiroidei" candidata Antonella Caroli - "Risposta terapeutica ai farmaci ad azione incretinica: Studio osservazionale retrospettivo in un contesto di pratica clinica ambulatoriale" candidata Sara Al-Khalaf - "Valutazione del grasso intrapancreatico in pazienti affetti da diabete mellito di tipo 2: aspetti clinici e fisiopatologici" candidato Giuseppe Varricchione - "Biomarcatori del metabolismo osseo e profilo di rischio cardiometabolico in pazienti con Diabete Mellito di Tipo 2" candidata Valentina Ceccarelli - "Impatto della pandemia da COVID-19 sul controllo glicometabolico dei pazienti con diabete mellito di tipo I" candidata Alessia Alfonsi - "Parametri metabolici e infiammatori associati ad alterazioni ossee nel diabete mellito di tipo 2" candidata Maria Luongo

Part V - Society memberships, Awards and Honors

Year	Institution	Title
2019	European Association for the study of the Liver (EASL)	<i>NAFLD Summit, Seville, 2019 Young Researcher Full Grant</i>
2018	Italian Diabetes Society (SID)	<i>EASD Meeting, Berlin, 2018 Travel Grant</i>
2018	European Association for the study of the Liver (EASL)	<i>NAFLD Summit, Geneve, 2018 Young Researcher Full Grant</i>
2018	European Association for the study of the Liver (EASL)	<i>EASL "Gut-Liver Axis" Conference, Leuven, 2018 Young Researcher Full Grant</i>
2017	European Association for the study of the Liver (EASL)	<i>NAFLD Summit, Rome, 2017 Young Researcher Grant</i>
2017	Italian Diabetes Society (SID)	<i>Prize "Umberto Di Mario"</i>
2016	Italian Diabetes Society (SID)	<i>EASD Meeting, Munich, 2016 Travel Grant</i>
2016	European Association for the study of the Liver (EASL)	<i>International Liver Conference, 2016 Award for the Best Poster</i>
2016	European Association for the study of the Liver (EASL)	<i>International Liver Conference, 2016 Young Researcher Full Travel Grant</i>
2014	Fondazione DiabeteRicerca Italian Diabetes Society (SID)	<i>1-year Fellowship for conducting a research project abroad on diabetes</i>
2014	Italian Society of Internal Medicine (SIMI)	<i>Prize "Alberto Malliani" Young Investigator Award</i>
2013	DEIduemila	<i>DEIduemila Prize Young Researcher in Endocrinology</i>
2012	Parma Diabete - IX Edition; Italian Diabetes Society (SID)	<i>Young Investigator Award</i>
2010	Clinical School of Hepatology, Course in "Metabolic Liver Diseases"	<i>Young Researcher Full Grant</i>
2008	Italian Society of Internal Medicine (SIMI) - Sanofi Aventis Foundation Prize	<i>Young Investigator Award</i>
Since 2010	Italian Diabetes Society (SID)	<i>Member</i>
Since 2011	European Association for the study of Diabetes (EASD)	<i>Member</i>
Since 2016	European Association for the study of the Liver (EASL)	<i>Member</i>
Since 2008	Immunotherapy Diabetes (IMDIAB)	<i>Member</i>
Since 2010	Study group on Atherosclerosis, SID	<i>Member</i>

Speaker to International conferences hosted by scientific societies

28/09/2021	Oral Communication 57th EASD Meeting - Online	<i>"Pro-neurotensin levels and the prediction of cardiovascular risk in individuals with type 1 diabetes: a longitudinal study with 10-year follow-up"</i>
------------	--	--

08/12/2020	Oral Communication EGIR (<i>European Group for the Study of Insulin Resistance</i>) & NAFLD EASD Study Group Meeting	<i>"Reduced biliverdin reductase-A expression in visceral adipose tissue is associated with adipocyte dysfunction and NAFLD in human obesity"</i>
22/09/2020	Oral Communication 56th EASD Meeting - Online	<i>"Relationship between hepatic and systemic angiopoietin-like 3, hepatic Vitamin D receptor expression and non-alcoholic fatty liver disease in obesity"</i>
22/09/2020	Chairperson 56th EASD Meeting	Poster Section on <i>"Type 2 diabetes treatment IRL"</i>
14/10/2019	Invited Lecture Italian-Swedish Health Summit on Diabetes and Cardiovascular Disease, Karolinska Institute – Stockholm, Sweden	<i>"NAFLD/NASH and chronic vascular complications of type 2 diabetes"</i>
26/09/2019	ePoster Oral Presentation - EASL International Summit on Non-Alcoholic Fatty Liver Disease, Sevilla, Spain.	<i>"Increased hepatic Angiopoietin-Like Protein 3 is associated with NAFLD and with liver expression of vitamin D receptor and vitamin D hydroxylases"</i>
18/09/2019	ePoster Oral Presentation 55th EASD Meeting, Barcelona, Spain.	<i>"Elevated plasma copeptin levels identify non-alcoholic fatty liver disease in obese individuals with and without type 2 diabetes"</i>
14/03/2019	Invited Lecture 15th Congress of the Spanish Society of Obesity SEEDO – SEO, Vigo, Spain.	<i>"Neurotensin and Fatty Liver"</i>
05/10/2018	Oral Communication 54th EASD Meeting, Berlin, Germany.	<i>"Elevated plasma proneurotensin levels predict NAFLD and visceral adipose tissue inflammation in adults with and without type 2 diabetes"</i>
20/09/2018	ePoster Oral Presentation - EASL International Summit on Non-Alcoholic Fatty Liver Disease, Geneva, Switzerland	<i>"Increased liver expression of Vitamin D Receptor is associated with NAFLD, visceral obesity and adipose tissue inflammation"</i>
08/06/2018	ePoster Oral Presentation EASL Gut-Liver Axis Monothematic Conference, Leuven Belgium.	<i>"Increased plasma proneurotensin levels identify NAFLD in adults with and without type 2 diabetes"</i>
09/11/2017	ePoster Oral Presentation EASL International Summit on Non-Alcoholic Fatty Liver Disease, Rome, Italy.	<i>"Increased circulating proneurotensin levels identify non-alcoholic fatty liver disease in obese subjects with and without type 2 diabetes"</i>
14/09/2017	Oral Communication 53th EASD Meeting, Lisbon, Portugal.	<i>"Plasma WISP1 is a marker of systemic and adipose tissue inflammation in subjects with type 2 diabetes"</i>
13/09/2016	Poster Oral Presentation 52th EASD Meeting, Munich, Germany.	<i>"Phenotypical heterogeneity linked to adipose tissue dysfunction in patients with type 2 diabetes"</i>
15/04/2016	Poster Oral Presentation International Liver Congress EASL Barcelona, Spain.	<i>"Effects of oral high-dose vitamin d supplementation on non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled trial"</i>
03/10/2012	Poster Oral Presentation 48th EASD Meeting, Berlin, Germany.	<i>"The association between hypovitaminosis D and metabolic syndrome is not dependent on body fat mass"</i>

Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Role	Grant Value (Euro)
------	-------	---------	------	--------------------

2013	"Studio dell'attività lipoproteinlipasica post-eparinica in portatori della variante 40K del gene ANGPTL4"	"Avvio alla Ricerca" Sapienza University	PI	3.000
2014	"Associazione tra polimorfismo Cdx2 del recettore della vitamina D (VDR) e diabete mellito di tipo 2"	"Avvio alla Ricerca" Sapienza University	PI	3.900
2015	"Valore predittivo di OPN nell'identificare un profilo di rischio cardio-metabolico più severo e malattia cardiovascolare subclinica in pazienti affetti da diabete mellito di tipo 2 senza complicanze micro e macrovascolari del diabete"	"Avvio alla Ricerca" Sapienza University	PI	2.100
2016	"Interplay between dipeptidyl peptidase-4 and vitamin D in adipose tissue-bone axis in patients with type 2 diabetes"	Fondazione Eli Lilly "La Ricerca in Italia. Un'idea per il Futuro"	PI	210.000
2017	"A randomized, double blind placebo controlled clinical trial to assess the efficacy and safety of sitagliptin on bone measures in women affected by type 2 diabetes. A gender-oriented approach to address a gender-specific frailty. The SLOWDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) study"	AIFA Finanziamento per la Ricerca Indipendente 2016: <i>Referente Scientifico</i>	I	495.000

Part VII – Research Activities

Keywords	Brief Description
Type 2 Diabetes Glucose Regulation Metabolic Syndrome	Phenotypical heterogeneity of patients with type 2 diabetes. Genetics of type 2 diabetes and impaired glucose regulation.
NAFLD/NASH Gut-Liver Axis Insulin Resistance	Clinical outcomes of NAFLD/NASH in dysmetabolic patients Study of gut-derived peptides and metabolites in the association between overweight/obesity and metabolic impairment (insulin resistance, NAFLD, type 2 diabetes)
Adipose Tissue Inflammation Insulin Resistance	Study of the adipose tissue inflammation / dysfunction as a determinant of insulin resistance and dysmetabolic trait in individuals with and without obesity and type 2 diabetes
Vitamin D deficiency VD/VDR axis	Study of the association between vitamin D status and metabolic diseases. Gene variants associated with altered vitamin D metabolism. Effects of vitamin D supplementation on metabolic outcomes.
Type 2 Diabetes Bone metabolism	Study of bone metabolism in relation to the presence of type 2 diabetes; association between systemic dipeptidyl-peptidase 4 activity and bone health. Effects of dipeptidyl-peptidase 4 inhibition on markers of bone turnover and mineralization in type 2 diabetes

National and International research collaborations

Period	Group/Project	Research area
2005-2009	GENFIEV Project Italian Diabete Society (SID) P.I. Prof. Stefano Del Prato	GENFIEV " <i>Genetica fisiopatologia ed evoluzione del diabete mellito di tipo 2</i> "
Since 2008	IMDIAB Group - Immunotherapies in Diabetes P.I. Prof. Paolo Pozzilli	Immune intervention therapies at the diagnosis in patients with type 1 diabetes

Since 2015	SUMMER Study Group P.I. Prof. Vincenzo Trischitta	SUMMER- <i>Sapienza University Mortality and Morbidity Event Rate (SUMMER) study in diabetes</i>
Since 2015	Prof. Olle Melander, Head of the Division of Hypertension and Cardiovascular Disease Department of Clinical Sciences CRC- Clinical Research Centre, Lund University, Malmö, Sweden	-Role of the gut peptide Neurotensin in metabolic disorders, adipose tissue dysfunction and body fat distribution -Copeptin in metabolic diseases
Since 2015	Prof. Corrado M. Cilio Diabetes and Immunovirology Unit Department of Clinical Sciences CRC- Clinical Research Centre, Lund University, Malmö, Sweden	Epigenetic modifications in type 1 diabetes

Participation to International Clinical Trials

Year	Role	Title
2007-2011	Investigator Study Coordinator	International, Randomised Clinical Trial - <i>Andromeda 901: double-blind Diapep 277 vs placebo in type 1 diabetes at diagnosis</i>
2008-2011	Investigator Study Coordinator	International, Multicenter, Randomised Clinical Trial DEFEND-1: <i>A Phase 3 Trial with Otelixizumab (a humanized anti-CD3 MAb) in type 1 diabetes</i>
2011-2014	Investigator Study Coordinator	International, Multicenter, Randomised Clinical Trial Andromeda 1001: <i>A Phase 3, Multinational, Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Study To Investigate The Clinical Efficacy And Safety Of Diapep277® In Newly Diagnosed Type 1 Diabetes Subjects</i>
2016-2018	Investigator	International, Multicenter, Prospective Study REFLECT: <i>Studio prospettico, non interventistico, multicentrico per la valutazione della sicurezza e dell'efficacia di insulina degludec in una popolazione di pazienti con diabete mellito tipo 1 e 2 nella reale pratica clinica</i>
2017-2019	Investigator Study Coordinator	International, Multicenter Randomised Clinical Trial PRONTO-T1D (I8B-MC-ITRM) - <i>A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes</i>
2018-2019	Investigator	International, Multicenter, Clinical Trial SAGE: <i>Multinational, crosssectional, observational study to describe glycemic control and quality of life for type 1 diabetic adult patients.</i>
2018-2020	Investigator Study Coordinator	International, Multicenter, Clinical Trial INSAX - <i>In-market utilisation of liraglutide used for weight management in Europe: a retrospective medical record review study</i>
2019-2020	Investigator	International, Multicenter, Clinical Trial EU-CAPTURE - <i>A non-interventional cross-sectional study to capture the prevalence of cardiovascular disease in patients with type 2 diabetes in selected Countries in Europe</i>
2019-	Investigator Study Coordinator	International, Multicenter, Randomised Clinical Trial FLOW - <i>Effetti di semaglutide rispetto al placebo sulla progressione dell'insufficienza renale in soggetti con diabete di tipo 2 e malattia renale cronica</i>

List of peer-reviewed articles in International journals (Scopus / ISI Web of Science)

Cimini FA*, **Barchetta I***, Zuliani I, Pagnotta S, Bertocchini L, Dule S, Zampieri M, Reale I A, Baroni MG, Cavallo MG, Barone E. Biliverdin Reductase-A Protein Levels Are Reduced in Type 2 Diabetes and Are Associated with Poor

Glycometabolic Control. Life Sci. 2021 Aug 26;284:119913. doi: 10.1016/j.lfs.2021.119913. PMID: 34453944. <i>*Co-first authorship.</i>
Cimini FA*, Barchetta I* , Bertoccini L, Ceccarelli V, Baroni MG, Melander O, Cavallo MG. High pro-neurotensin levels in individuals with type 1 diabetes associate with the development of cardiovascular risk factors at follow-up. Acta Diabetol. 2021 Aug 29. doi: 10.1007/s00592-021-01783-x. Epub ahead of print. PMID: 34455471. <i>*Co-first authorship.</i>
Leto G, Barchetta I , De Candia L, Magotti MG, Cianciullo M, Manti R, Negri C, Cimino V, Dodesini AR, Zerella F, Baratta R. Identification of the Inappropriate Clinical Actions (DON'T) to Improve the Management of Patients with Type 2 Diabetes Failing Basal Insulin Supported Oral Treatment: Results of Survey for a Panel of Diabetes Specialists in Italy. Diabetes Ther. 2021 Aug 20. doi: 10.1007/s13300-021-01137-4. Epub ahead of print. PMID: 34415563.
Bertoccini L, Bailetti D, Sentinelli F, Cimini F.A, Barchetta I , Mannino AC, Cossu E, Leonetti F, Cavallo MG, Baroni MG. The rs45454496 (E1813K) variant in the adiposity gene ANK2 doesn't associate with obesity in Southern European subjects. Gene Reports, 24, Sept 2021; 10.1016/j.genrep.2021.101303.
Barchetta I , Arvastsson J, Sarmiento L, Cilio CM. Epigenetic Changes Induced by Maternal Factors during Fetal Life: Implication for Type 1 Diabetes. Genes (Basel). 2021 Jun 8;12(6):887. doi: 10.3390/genes12060887. PMID: 34201206; PMCID: PMC8227197.
Barchetta I , Dule S, Bertoccini L, Cimini FA, Sentinelli F, Bailetti D, Marini G, Barbonetti A, Loche S, Cossu E, Cavallo MG, Baroni MG. The single-point insulin sensitivity estimator (SPISE) index is a strong predictor of abnormal glucose metabolism in overweight/obese children: a long-term follow-up study. J Endocrinol Invest. 2021 Jun 17. doi: 10.1007/s40618-021-01612-6. Epub ahead of print. PMID: 34142364.
Zampieri M, Bacalini MG, Barchetta I , Scalea S, Cimini FA, Bertoccini L, Tagliatesta S, De Matteis G, Zardo G, Cavallo MG, Reale A. Increased PARYlation impacts the DNA methylation process in type 2 diabetes mellitus. Clin Epigenetics. 2021 May 17;13(1):114. doi: 10.1186/s13148-021-01099-1. PMID: 34001206; PMCID: PMC8130175.
Barchetta I , Bertoccini L, Sentinelli F, Bailetti D, Marini G, Cimini FA, Ceccarelli V, Struck J, Schulte J, Loche S, Cossu E, Melander O, Cavallo MG, Baroni MG. Circulating pro-neurotensin levels predict bodyweight gain and metabolic alterations in children. Nutr Metab Cardiovasc Dis. 2021 Mar 10;31(3):902-910. doi: 10.1016/j.numecd.2020.11.025. Epub 2020 Dec 5. PMID: 33549442.
Cimini FA, Barchetta I , et al. Granzyme B Expression in Visceral Adipose Tissue Associates With Local Inflammation and Glyco-Metabolic Alterations in Obesity. Front Immunol. 2020 Nov 18;11:589188. doi: 10.3389/fimmu.2020.589188. PMID: 33312176; PMCID: PMC7708321.
Velotti F, Barchetta I , Cimini FA, Cavallo MG. Granzyme B in Inflammatory Diseases: Apoptosis, Inflammation, Extracellular Matrix Remodeling, Epithelial-to-Mesenchymal Transition and Fibrosis. Front Immunol. 2020 Nov 11;11:587581. doi: 10.3389/fimmu.2020.587581. PMID: 33262766; PMCID: PMC7686573.
Ceccarelli V, Barchetta I , et al. Reduced Biliverdin Reductase-A Expression in Visceral Adipose Tissue is Associated with Adipocyte Dysfunction and NAFLD in Human Obesity. Int J Mol Sci. 2020 Nov 29;21(23):9091. doi: 10.3390/ijms21239091. PMID: 33260451; PMCID: PMC7730815.
Barchetta I , Cimini FA, Cavallo MG. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update. Nutrients. 2020 Oct 28;12(11):3302.
Barchetta I , Cimini FA, Bertoccini L, Ceccarelli V, Spaccarotella M, Baroni MG, Cavallo MG. Effects of work status changes and perceived stress on glycaemic control in individuals with type 1 diabetes during COVID-19 lockdown in Italy. Diabetes Research and Clinical Practice. 2020 Dec;170:108513.
Barchetta I , Chiappetta C, Ceccarelli V, Cimini FA, Bertoccini L, Gaggini M, Cristofano CD, Silecchia G, Lenzi A, Leonetti F, Baroni MG, Gastaldelli A, Cavallo MG. Angiopoietin-Like Protein 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase. Int J Mol Sci. 2020 Sep 29;21(19):E7197. doi: 10.3390/ijms21197197. PMID: 33003532
Barchetta I , Ceccarelli V, Cimini FA, et al. Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease [published online ahead of print, 2020 Aug 27]. J Endocrinol Invest. 2020;10.1007/s40618-020-01392-5.
Barchetta I , Cimini FA, Chiappetta C, et al. Relationship between hepatic and systemic angiopoietin-like 3, hepatic Vitamin D receptor expression and NAFLD in obesity [published online ahead of print, 2020 Jun 8]. Liver Int. 2020;10.1111/liv.14554.

Cimini FA*, Barchetta I* , Ciccarelli G, et al. Adipose tissue remodelling in obese subjects is a determinant of presence and severity of fatty liver disease [published online ahead of print, 2020 May 29]. <i>Diabetes Metab Res Rev.</i> 2020;e3358. doi:10.1002/dmrr.3358 * <i>Co-first authorship.</i>
Barchetta I , Gisella Cavallo M, Giorgio Baroni M. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications. <i>Diabetes Res Clin Pract.</i> 2020 Apr 22;108165 (1)
Cimini FA, Barchetta I , et al. Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease. <i>World J Gastrointest Pathophysiol.</i> 2019;10(2):11-6.
Barchetta I , Ciccarelli G, Barone E, et al. Greater circulating DPP4 activity is associated with impaired flow mediated dilatation in adults with type 2 diabetes mellitus. <i>NMCD</i> 2019 Oct;29(10):1087-94.
Barchetta I , Cimini FA, Ciccarelli G, et al. Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation. <i>J Endocrinol Invest.</i> 2019 Nov;42(11):1257-72.
Sarmiento L, Svensson J, Barchetta I , et al. Copy number of the X-linked genes TLR7 and CD40L influences innate and adaptive immune responses. <i>Scand J Immunol.</i> 2019 Aug;90(2):e12776.
Barchetta I , Enhörning S, Cimini FA, et al. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity. <i>BMC Med.</i> 2019 Apr 30;17(1):85.
Cimini FA*, Arena A*, Barchetta I* , et al. Reduced biliverdin reductase-A levels are associated with early alterations of insulin signaling in obesity. <i>Biochim Biophys Acta Mol Basis Dis.</i> 2019. * <i>Co-first authorship.</i>
Bertoccini L, Sentinelli F, [...] Cimini FA, Barchetta I , et al. Circulating miRNA-375 levels are increased in autoantibodies-positive first-degree relatives of type 1 diabetes patients. <i>Acta Diabetol.</i> 2019 Feb 13.
Cimini FA, D'Eliseo D, Barchetta I , Bertoccini L, Velotti F, Cavallo MG. Increased circulating granzyme B in type 2 diabetes patients with low-grade systemic inflammation. <i>Cytokine.</i> 2018 Nov 22.
Barchetta I , Cavallo MG. Technological Support to Intensive Insulin Therapy by a Novel Smartphone Application in Young Adults With Type 1 Diabetes: One Center's Experience. <i>J Diabetes Sci Technol.</i> 2018.
Barchetta I , Ceccarelli V, Cimini FA et al. Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus. <i>J Endocrinol Invest.</i> 2018 Aug21.
Beveridge LA, Khan F, Struthers AD, Armitage J, Barchetta I , et al. Effect of vitamin D supplementation on markers of vascular function - a systematic review and individual participant meta-analysis. <i>J Am Heart Assoc.</i> 2018 May 30;7(11):e008273. doi: 10.1161/JAHA.117.008273. PMID: 29848497; PMCID: PMC6015391.
Barchetta I , Cimini FA, Leonetti F, et al. Increased plasma proneurotensin levels identify NAFLD in adults with and without type 2 diabetes. <i>J Clin Endocrinol Metab.</i> 2018 Jun 1;103(6):2253-2260. doi: 10.1210/jc.2017-02751. PMID: 29590379.
Barchetta I , Ciccarelli G, Cimini FA, et al. Association between systemic leptin and neurotensin concentration in adult individuals with and without type 2 diabetes mellitus. <i>J Endocrinol Invest.</i> 2018 Oct;41(10):1159-1163. doi: 10.1007/s40618-018-0845-9. Epub 2018 Feb 7. PMID: 29417469.
Barchetta I , Cimini FA, Capoccia D, et al. Neurotensin Is a Lipid-Induced Gastrointestinal Peptide Associated with Visceral Adipose Tissue Inflammation in Obesity. <i>Nutrients.</i> 2018 Apr 23;10(4). pii: E526.
Cossu E, [...] Barchetta I , et al. Presence of diabetes-specific autoimmunity in women with gestational diabetes mellitus (GDM) predicts impaired glucose regulation at follow-up. <i>J Endocrinol Invest.</i> 2018;41(9):1061-8.
Bertoccini L, Sentinelli F, Incani M, [...] Barchetta I , et al. The Arg282Ser missense mutation in APOA5 gene determines a reduction of triglyceride and LDL-cholesterol in children, together with low serum levels of apolipoprotein A-V. <i>Lipids Health Dis.</i> 2017 Sep 19;16(1):179.
Barchetta I , Cimini FA, Cavallo MG. Vitamin D Supplementation and Non-Alcoholic Fatty Liver Disease: Present and Future. <i>Nutrients.</i> 2017 Sep 14;9(9):1015. doi: 10.3390/nu9091015. PMID: 28906453; PMCID: PMC5622775.
Cimini FA, Barchetta I , Porzia A, et al. Circulating IL-8 levels are increased in patients with type 2 diabetes and associated with worse inflammatory and cardiometabolic profile. <i>Acta Diabetol.</i> 2017 Aug 23.
Cimini FA, Barchetta I , et al. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of

non-alcoholic fatty liver disease. <i>World J Gastroenterol.</i> 2017 May 21;23(19):3407-17.
Barchetta I , Cimini FA, Capoccia D, et al. WISP1 Is a Marker of Systemic and Adipose Tissue Inflammation in Dysmetabolic Subjects With or Without Type 2 Diabetes, <i>J Endocr Soc.</i> 2017 Apr 18;1(6):660-70.
Barchetta I , Del Ben M, Angelico F, et al. Comment on Elangovan H et al. Vitamin D in liver disease: Current evidence and potential directions. <i>Biochim Biophys Acta</i> 2017;1863(4):907-916.
Bertocchini L, Sentinelli F, Leonetti F, [...] Barchetta I , et al. The Vitamin D Receptor (VDR) functional variant rs2228570 (C>T) does not associate with Type 2 Diabetes Mellitus (T2DM). <i>Endocr Res.</i> 2017;42(4):331-5.
Sarmiento L, Frisk G, Anagandula M, Hodik, M, Barchetta I , et al. Echovirus 6 Infects Human Exocrine and Endocrine Pancreatic Cells and Induces Pro-Inflammatory Innate Immune Response. <i>Viruses</i> 2017, 9, 25.
Barchetta I , Angelico F, Del Ben M, et al. Phenotypical heterogeneity linked to adipose tissue dysfunction in patients with Type 2 diabetes. <i>Clin Sci (Lond).</i> 2016 Oct 1;130(19):1753-62.
Barchetta I , Cimini FA, Bloise D, Cavallo MG. Dipeptidyl peptidase-4 inhibitors and bone metabolism: is vitamin D the link? <i>Acta Diabetol.</i> 2016 Oct;53(5):839-44.
Barchetta I , et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. <i>BMC Med.</i> 2016;14:92.
Sentinelli F, Bertocchini L, Barchetta I , et al. The vitamin D receptor (VDR) gene rs11568820 variant is associated with type 2 diabetes and impaired insulin secretion in Italian adult subjects, and associates with increased cardio-metabolic risk in children. <i>Nutr Metab Cardiovasc Dis.</i> 2016 May;26(5):407-13. doi: 10.1016/j.numecd.2016.02.004. Epub 2016 Feb 19. PMID: 27052925.
Barchetta I , Alessandri C, Bertocchini L, et al. Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile. <i>EJE</i> 174,2 (2016): 187-92.
Barchetta I , Capoccia D, Baroni MG, et al. The “Sapienza University Mortality and Morbidity Event Rate (SUMMER) Study in Diabetes”: Study Protocol group. <i>Nutr Metab Cardiovasc Dis.</i> 2016 Feb;26(2):103-8.
Di Franco M, Barchetta I , Iannuccelli C, et al. Hypovitaminosis D in recent onset rheumatoid arthritis is predictive of reduced response to treatment and increased disease activity: a 12-month follow-up study. <i>BMC Musculoskelet Disord.</i> 2015 Mar 15;16:53.
Barchetta I , Guglielmi C, Bertocchini L, et al. Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control. <i>Acta Diabetol.</i> 2015 Feb 27.
Barchetta I , Baroni MG, Leonetti F, et al. TSH levels are associated with vitamin D status and seasonality in an adult population of euthyroid adults. <i>Clin Exp Med.</i> 2015 Aug;15(3):389-96.
Barchetta I , De Bernardinis M, Capoccia D, et al. Hypovitaminosis D is independently associated with metabolic syndrome in obese patients. <i>PLoS One.</i> 2013 Jul 31;8(7):e68689.
Bianchi C, Miccoli R, Trombetta M, et al; GENFIEV Investigators . Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β -cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study. <i>J Clin Endocrinol Metab.</i> 2013 May;98(5):2100-5.
Napoli N, Strollo R, Pitocco D, et al; IMDIAB Group . Effect of calcitriol on bone turnover and osteocalcin in recent-onset type 1 diabetes. <i>PLoS One.</i> 2013;8(2): e56488.
Cavallo MG, Sentinelli F, Barchetta I , et al. Altered glucose homeostasis is associated with increased serum apelin levels in type 2 diabetes mellitus. <i>PLoS One.</i> 2012;7(12):e51236.
Barchetta I , Carotti S, Labbadia G, et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. <i>Hepatology</i> 2012 Dec;56(6):2180-7.
Barchetta I , Angelico F, Del Ben M, et al. Strong association between non-alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. <i>BMC Med.</i> 2011,9(1):85.
Barchetta I , Riccieri V, Vasile M, et al. High prevalence of capillary abnormalities in patients with diabetes and association

with retinopathy. Diabet Med. 2011 Sep;28(9):1039-44.
Bizzarri C, Pitocco D, Napoli N, et al; IMDIAB Group . No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. Diabetes Care. 2010 Sep;33(9):1962-3.
Bianchi C, Miccoli R, Bonadonna RC et al; GENFIEV Investigators . Metabolic syndrome in subjects at high risk for type 2 diabetes: the genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. Nutr Metab Cardiovasc Dis. 2011 Sep;21(9):699-705.
Pozzilli P, Strollo R, Barchetta I . Natural history and immunopathogenesis of type 1 diabetes. Endocrinol Nutr. 2009 Dec;56 Suppl 4:50-2. Review. PubMed PMID: 20629233.
Barchetta I , Sperduti L, Germanò G, Valiante S, Vestri A, Fraioli A, Baroni MG, Cavallo MG. Subclinical vascular alterations in young adults with type 1 diabetes detected by arterial tonometry. Diabetes Metab Res Rev. 2009 Nov; 25(8): 756-61.

Part VIII – Summary of Scientific Achievements

Product type	Number	Data Base
Papers [international]	64	Scopus
Papers [national]	1	Google Scholar
Books [scientific]	0	
Books [teaching]	0	

Total Impact factor (IF) (in relation to year of publication)	255	Scopus
Average IF per Product (in relation to year of publication)	3.98	Scopus
Total Citations	1204	Scopus
Average Citations per Product	18.81	Scopus
Hirsch (H) index	18	Scopus
Normalized H index*	18/13 = 1.38	Scopus

*H index divided by the academic seniority.

Part IX– Selected Publications

1. Cimini FA*, **Barchetta I***, Bertocchini L, Ceccarelli V, Baroni MG, Melander O, Cavallo MG. High pro-neurotensin levels in individuals with type 1 diabetes associate with the development of cardiovascular risk factors at follow-up. Acta Diabetol. 2021 Aug 29. doi: 10.1007/s00592-021-01783-x. Epub ahead of print. PMID: 34455471. ***Co-first authorship. IF (year of publication): 4.280; IF (2020 InCites): 4.280; Citations: 0**
2. **Barchetta I**, Dule S, Bertocchini L, Cimini FA, Sentinelli F, Bailetti D, Marini G, Barbonetti A, Loche S, Cossu E, Cavallo MG, Baroni MG. The single-point insulin sensitivity estimator (SPISE) index is a strong predictor of abnormal glucose metabolism in overweight/obese children: a long-term follow-up study. J Endocrinol Invest. 2021 Jun 17. doi: 10.1007/s40618-021-01612-6. Epub ahead of print. PMID: 34142364. **IF (year of publication): 4.256, IF (2020 InCites): 4.256; Citations: 0**
3. Cimini FA*, **Barchetta I***, Zuliani I, Pagnotta S, Bertocchini L, Dule S, Zampieri M, Reale A, Baroni Mg, Cavallo MG, Barone E. Biliverdin reductase-A protein levels are reduced in type 2 diabetes and are associated with poor glycometabolic control. Life Sci. 2021 Aug 26;284:119913. doi: 10.1016/j.lfs.2021.119913. ***Co-first authorship. IF (year of publication): 5.037, IF (2020 InCites): 5.037; Citations: 1**
4. **Barchetta I**, Bertocchini L, Sentinelli F, Bailetti D, Marini G, Cimini FA, Ceccarelli V, Struck J, Schulte J, Loche S,

Cossu E, Melander O, Cavallo MG, Baroni MG. Circulating pro-neurotensin levels predict bodyweight gain and metabolic alterations in children. *Nutr Metab Cardiovasc Dis.* 2021 Mar 10;31(3):902-910. doi: 10.1016/j.numecd.2020.11.025. Epub 2020 Dec 5. PMID: 33549442. **IF (year of publication): 4.222, IF (2020 InCites): 4.222; Citations: 3**

5. **Barchetta I**, Ceccarelli V, Cimini FA, Barone E, Sentinelli F, Coluzzi M, Chiappetta C, Bertocchini L, Tramutola A, Labbadia G, Di Cristofano C, Silecchia G, Leonetti F, Cavallo MG. Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease. *J Endocrinol Invest.* 2021 May;44(5):979-988. doi: 10.1007/s40618-020-01392-5. Epub 2020 Aug 27. PMID: 32852705; PMCID: PMC8049937. **IF (year of publication): 4.256, IF (2020 InCites): 4.256; Citations: 3**
6. Cimini FA*, **Barchetta I***, Ciccarelli G, Leonetti F, Silecchia G, Chiappetta C, Di Cristofano C, Capoccia D, Bertocchini L, Ceccarelli V, Carletti R, Fraioli A, Baroni MG, Morini S, Cavallo MG. Adipose tissue remodelling in obese subjects is a determinant of presence and severity of fatty liver disease. *Diabetes Metab Res Rev.* 2021 Jan;37(1):e3358. doi: 10.1002/dmrr.3358. * *Co-first authorship.* **IF (year of publication): 4.876, IF (2020 InCites): 4.876; Citations: 9**
7. **Barchetta I**, Chiappetta C, Ceccarelli V, Cimini FA, Bertocchini L, Gaggini M, Di Cristofano C, Silecchia G, Lenzi A, Leonetti F, Baroni MG, Gastaldelli A, Cavallo MG. Angiopoietin-Like Protein 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase. *Int J Mol Sci.* 2020 Sep 29;21(19):7197. doi: 10.3390/ijms21197197. **IF (year of publication): 5.923, IF (2020 InCites): 5.923; Citations: 3**
8. **Barchetta I**, Cimini FA, Bertocchini L, Ceccarelli V, Spaccarotella M, Baroni Mg, Cavallo MG. Effects of work status changes and perceived stress on glycaemic control in individuals with type 1 diabetes during COVID-19 lockdown in Italy. *Diabetes Res Clin Pract.* 2020 Dec;170:108513. doi: 10.1016/j.diabres.2020.108513. Epub 2020 Oct 16. **IF (year of publication): 5.602, IF (2020 InCites): 5.602; Citations: 8**
9. **Barchetta I**, Cimini FA, Chiappetta C, Bertocchini L, Ceccarelli V, Capoccia D, Gaggini M, Di Cristofano C, Della Rocca C, Silecchia G, Leonetti F, Lenzi A, Gastaldelli A, Cavallo MG. Relationship between hepatic and systemic angiopoietin-like 3, hepatic Vitamin D receptor expression and NAFLD in obesity. *Liver Int.* 2020 Sep;40(9):2139-2147. doi: 10.1111/liv.14554. Epub 2020 Jun 28. PMID: 32510837. **IF (year of publication): 5.828, IF (2020 InCites): 5.828; Citations: 6**
10. Cimini FA*, Arena A*, **Barchetta I***, Tramutola A, Ceccarelli V, Lanzillotta C, Fontana M, Bertocchini L, Leonetti F, Capoccia D, Silecchia G, Di Cristofano C, Chiappetta C, Di Domenico F, Baroni MG, Perluigi M, Cavallo MG, Barone E. Reduced biliverdin reductase-A levels are associated with early alterations of insulin signaling in obesity. *Biochimica Biophysica Acta. Molecular Basis Of Disease*, 2019 doi:10.1016/j.bbadis.2019.02.021 * *Co-first authorship.* **IF (year of publication): 4.352, IF (2020 InCites): 5.187; Citations: 18**
11. **Barchetta I**, Enhörning S, Cimini F A, Capoccia D, Chiappetta C, Di Cristofano C, Silecchia, Gianfranco, Leonetti F, Melander O, Cavallo MG. Elevated plasma copeptin levels identify the presence and severity of nonalcoholic fatty liver disease in obesity. *BMC Medicine*, 2019 vol. 17, ISSN: 1741-7015, doi: 10.1186/s12916-019-1319-4. **IF (year of publication): 6.782, IF (2020 InCites): 8.775; Citations: 8**
12. **Barchetta I**, Cimini F A, Leonetti F, Capoccia D, Di Cristofano C, Silecchia G, Orho-Melander M, Melander O, Cavallo M G. Increased plasma proneurotensin levels identify NAFLD in adults with and without type 2 diabetes. *J Clin Endocrinol Metab.* 2018 Mar 23. doi: 10.1210/jc.2017-02751. **IF (year of publication): 5.605, IF (2020 InCites): 5.958; Citations: 24**
13. **Barchetta I**, Cimini FA, Capoccia D, Bertocchini L, Ceccarelli V, Chiappetta C, Leonetti F, Di Cristofano C, Silecchia G, Orho-Melander M, Melander O, Cavallo MG. Neurotensin Is a Lipid- Induced Gastrointestinal Peptide Associated with Visceral Adipose Tissue Inflammation in Obesity. *Nutrients.* 2018 Apr 23;10(4). **IF (year of publication): 4.171, IF (2020 InCites): 5.717; Citations: 30**
14. **Barchetta I**, Cimini FA, De Gioannis R, Ciccarelli G, Bertocchini L, Lenzi A, Baroni MG, Cavallo MG. Procollagen-III peptide identifies adipose tissue-associated inflammation in type 2 diabetes with or without non-alcoholic liver disease *Diabetes/Metabolism Res Rev* 2018, Vol. 5, ISSN: 1520-7552, doi: 10.1002/dmrr.2998. **IF (year of publication): 4.758, IF (2020 InCites): 4.876; Citations: 3**

15. **Barchetta I**, Cimini FA, Cavallo MG. Vitamin D Supplementation and Non-Alcoholic Fatty Liver Disease: Present and Future. *Nutrients*. 2017 Sep 14;9(9). doi: 10.3390/nu9091015. Review. **IF (year of publication): 4.196, IF (2020 InCites): 5.717; Citations: 31**


N.B. IF from Incites ISI Web); number of citations extracted from Scopus.

La sottoscritta, consapevole che – ai sensi dell’art. 76 del D.P.R. 445/2000 – le dichiarazioni mendaci, la falsità negli atti e l’uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali, dichiara che le informazioni riportate rispondono a verità.

La sottoscritta in merito al trattamento dei dati personali esprime il proprio consenso al trattamento degli stessi nel rispetto delle finalità e modalità di cui al d.lgs. n. 196/2003.

Roma, li 28.09.2021

Firma

A large black rectangular redaction box covering the signature area.